Miriam C. Sturkenboom, PhD

Professor
Department of Data Science & Biostatistics, Julius Global Health, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands, Netherlands

N/A

Poster(s):

• (093) Cohort event monitoring of COVID-19 vaccine safety using patient-reported outcomes in lactating women.
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (137) A Systematic Review to Summarize and Critically Appraise of Existing Phenotype Libraries Using Electronic Health Records- a FLOW study under the VAC4EU organisation
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST

• (154) Fit-for-purpose evaluation of Real-World Data for vaccines and medicines safety studies: the INSIGHT tool
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST

• (248) Cohort event monitoring of COVID-19 vaccine safety using patient-reported outcomes in pregnant women.
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (279) Maternal outcomes in women receiving COVID-19 vaccination during pregnancy compared with influenza vaccines in spontaneous reporting databases
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (288) Patterns of Prescribed and Dispensed Medicines among Non-Hospitalized Pregnant women with COVID-19: a Prospective Meta-analysis pooling findings from Healthcare Databases in Europe and North America
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (304) Prevalence of medication use for COVID-19 treatment in pregnancy: a two-stage individual patient data meta-analysis combining international registries.
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (328) A Comprehensive Review and Meta-analysis of COVID-19 Vaccine Studies in Vulnerable Populations- Analysis of 126 observational and clinical trials up to November 2022
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST

• (341) Evaluating impact of time-varying confounders in self-controlled risk interval analysis in a vaccine-safety cohort event monitoring-based simulation study
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (344) Interim results from the VAC4EU Post-Authorization Safety Study (PASS) among recipients of the Pfizer-BioNTech COVID-19 (Comirnaty®) vaccine in Europe
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (349) Patient-level prognostic models for COVID-19 vaccine effectiveness and safety: a systematic review
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (359) Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European Healthcare Data Sources: Methods and Results of the Second Study Feasibility Assessment
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST